

7 June 2023

Investor Webinar Presentation

Philadelphia and Phoenix US, 7 June 2023: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to provide a copy of its investor presentation as attached to this release.

Release authorised by

Vince Ippolito

Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofpironium Bromide for the treatment of primary axillary hyperhidrosis, through FDA approval. A mid-cycle review for the product has been successfully completed by FDA in 1Q 2023, which subject to other information that may be required by FDA, remains on track for approval for Q3 2023. Sofpironium Bromide is positioned to be a leading first line and second line therapy and represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Investor Webinar

June 2023

Important Notice & Disclaimer

1. Summary information

This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise indicated).

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Reliance should not be placed on information or opinions contained in this Presentation, and Botanix does not have any obligation to finalise, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www2.asx.com.au or at <https://botanixpharma.com/category/asx-releases/>.

2. Not an offer

Neither this Presentation nor any of its contents will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

3. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

4. Financial data

All dollar values are in United States dollars (\$) or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

5. Forward-looking statements and forecasts

This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Any such forward looking statements are also based on assumptions and contingencies which are subject to change and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix. Performance of any of the activities mentioned in this Presentation are dependent on funding being available at the relevant time and the activities may therefore change, or not be undertaken at all.

Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation. Botanix may also change the order or nature of the activities at its discretion and without notice.

6. No liability

The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents have authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, Botanix and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents:

expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

Operations:

3602 Horizon Drive, Suite 160
King of Prussia PA 19406


Corporate Office:

D2, 661 Newcastle Street
Leederville W. Australia 6007



Authorised for release by Vince Ippolito, Executive Chairman

Executing on planned commercial and regulatory milestones



Activities leading up to FDA approval

Initiation of label negotiations accelerates Botanix's commercial activities ready for launch

LABEL NEGOTIATIONS

- ❖ Planned to commence late Q2 2023 to be finalized before anticipated approval in Q3 2023

COMMERCIAL MANUFACTURING & PACKAGING

- ❖ Finalizing the branded packaging and timing manufacturing to coincide with launch

COMMERCIAL LAUNCH STRATEGY

- ❖ Rapidly establish SB Gel as a safe and effective first line treatment for hyperhidrosis

Label negotiations

Towards the end of the NDA review process, FDA and Botanix negotiate the drug's final package label

EFFICACY AND SAFETY DATA

- ❖ The label will reflect the efficacy and safety data that FDA and the Sponsor (Botanix) agrees needs to be included

DOSING AND ADMINISTRATION

- ❖ The label provides instructions for the dermatologist and patient about how SB Gel should be applied, how often and when

INDICATION AND CLAIMS

- ❖ Based on the age groups tested (in SB Gel's case, down to age 9), the label will specify those populations and target application area (ie underarm or axillary)

FINAL STEP IN THE APPROVAL PROCESS

- ❖ Once the label is agreed, no further reviews are required before FDA approval anticipated in September 2023

Commercial manufacturing and packaging

Utilizing same site as Phase 3 studies and at same scale and equipment

DRUG SUBSTANCE (API)

- ❖ Well-characterised synthetic process - room temperature stability >36 months
- ❖ Manufactured by same company as for our partner Kaken in Japan (at 450 kg scale)

DRUG PRODUCT (Gel)

- ❖ Process includes filling, capping and secondary packaging (cartons)
- ❖ Commercial contract manufacturer for US already appointed and manufactured 4x registration & 2x qualification batches at 200 kg scale


CONTAINER (Dispenser)

- ❖ Proprietary applicator to limit direct patient contact to the drug product during application
- ❖ Patents covering the container-closure system already submitted in key markets

PACKAGING (Label and IFU)


- ❖ Branded carton with trade name and logo
- ❖ Label and patient instructions for use included in final packaging

Efficient dermatologist targeting plus digital strategy—expands the addressable patient population



Hyperhidrosis: Significant Unmet Medical Need

When provided with a selection of key dermatologic indications, surveyed clinicians ranked hyperhidrosis last in their ability to successfully manage with available treatment options



Source: 1. Adapted from Cowen and Company Analyst Report dated February 27, 2019; survey executed by ExpertConnect. 2. 1 = most able to successfully manage; 6 = least able to successfully manage

SB Gel launch strategy

Rapidly establish SB Gel as a safe and effective first-line topical treatment of primary axillary hyperhidrosis, in patients 9 years of age and older

- Drive dermatology adoption through comprehensive engagement around a compelling clinical story
- Engage and motivate patients to take control of their hyperhidrosis and visit a telemedicine doctor for appropriate diagnosis and prescription
- Maximize favorable coverage through strategic contracting with insurance companies
- Provide patient access and immediate fulfillment through telemedicine and a pharmacy network, to drive trial and usage while optimizing profitability ('gross to net')
- Hire and train a highly effective sales force and target accordingly

Create tools to drive early adoption

Targeted at dermatologists and patients

- ❖ Creative
- ❖ Messaging
- ❖ Logo
- ❖ Carton
- ❖ Brand website
- ❖ Email
- ❖ Direct mail
- ❖ E-detail
- ❖ Placebo demonstration video
- ❖ Mechanism of action video



- ❖ Sales force leave behind
- ❖ Sales force objection handler
- ❖ Sales force generated emails
- ❖ Journal advertisement
- ❖ Clinical reprint
- ❖ HCP website
- ❖ HCP banner advertisements
- ❖ Congress booth & materials
- ❖ PR plan
- ❖ HCP SEO/SEM



Create consumer collateral to engage and motivate patients

Targeted at dermatologists and patients

- ❖ Consumer creative
- ❖ Consumer messaging
- ❖ Branded banners ads
- ❖ Consumer website
- ❖ Consumer print ad
- ❖ Consumer social media ads
- ❖ Consumer in-office materials
- ❖ Consumer digital video
- ❖ Patient advocacy plan
- ❖ Public relations plan
- ❖ Consumer medical plan
 - SEO/SEM
 - Social media
 - Print
 - Digital video
 - Banner ad placement



Implement insurance (payer) plans

PAYER VALUE PROPOSITION & KEY COMMUNICATIONS

- ❖ Compelling payer value proposition, leveraging market research/internal expertise
- ❖ Tools and resources to effectively communicate value proposition
- ❖ Communicate key product info to payers and channel at approval to expedite reimbursement and enable fulfillment

PRICING & CONTRACTING

- ❖ Supporting data to justify desired price point for SB Gel
- ❖ Contracting strategy supported by robust research and analysis

PAYER ENGAGEMENT

- ❖ Understanding of payers' intent and ability to manage hyperhidrosis category and SB Gel through market research/internal feedback
- ❖ Payer profiles and engagement plan to maximize access at FDA approval


PULL-THROUGH

- ❖ Resources to ensure dermatologists' confidence in the availability and affordability of SB Gel

Create a pharmacy network that is directly connected to a telemedicine provider, that will facilitate prescribing of SB Gel

PROPOSED PROGRAM DESIGN

Remove barriers to use by providing doctors with the ability to prescribe SB Gel at launch



Finalize contracts with partners that meet key criteria

Discussions underway

Telemedicine Partner

- ❖ History of experience
- ❖ Prescribing in all 50 states
- ❖ Exceeds industry standard for patient experience
- ❖ Provides end to end closed loop solution
- ❖ Supports a “digital first” approach
- ❖ Allows for asynchronous diagnosis and prescribing
- ❖ Experience with Dermatology & Consumer spaces

Pharmacy Partner

- ❖ Fulfillment in all 50 states
- ❖ Coordinates central filling to optimize data
- ❖ Provides weekly data refresh
- ❖ Average shipment time less than 3 days
- ❖ Enough space to allow for growth of program
- ❖ Patient interactions provided by licensed HCPs




Rapid scale up of sales force after FDA approval

- ❖ Rapid scale-up of a 20–30 rep field force
- ❖ Efficient & effective onboarding and initial training
- ❖ Targeted deployment in high value areas only

Comprehensive, pressure-tested, onboarding and training plan anchored to the key field activities that we initially target

Key live Sales meetings to provide training and certification to enable compliant and effective physician engagement

SALES FORCE ONBOARDING & TRAINING PLAN



Why we're excited about the Sofpironium Bromide opportunity

Significant Market Opportunity

- ❖ **Hyperhidrosis (HH) impacts >16M people in U.S**
- ❖ **~10M with axillary HH in U.S.**
- ❖ **Broad reimbursement already in place** (no need to get a code or new category)

Potential Best-in-Class

- ❖ **New chemical entity** specifically designed for axillary hyperhidrosis
- ❖ **Multiple ways to differentiate** (efficacy, safety, formulation, device)
- ❖ **First-to-market** outside U.S.

Robust Clinical Data

- ❖ **Positive and statistically significant results in U.S. and Japan P3 pivotal programs**
- ❖ **Completed U.S. and Japanese P3 long-term safety studies**
- ❖ **Exposure in >1,600 HH patients for U.S. NDA; submission expected mid-2022**

Launched in Japan


- ❖ **SB gel, 5% (ECCLOCK®) approved & launched in Japan** for primary axillary HH by Kaken Pharmaceutical
- ❖ **~300k units sold** in second year of launch

Global IP Protection

- ❖ **Comprehensive IP** in U.S. and other countries
- ❖ **Patent protection extends through 2040**

Source: 1. International Hyperhidrosis Society, 2. Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research

Executing on planned commercial and regulatory milestones



ersonal use only